Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Arteriovenous malformation (AVM) is a congenital vascular anomaly that progresses throughout
life and causes complications including tissue destruction due to rapid overgrowth, bleeding,
functional deficits, severe deformity and cardiac failure. Unfortunately, traditional
managements have transient benefits with more than 90 recurrence rate within a year.
Therefore, there is a significant unmet medical need. The purpose of this study is to assess
the safety and efficacy of Trametinib in children and adults with Extracranial Arteriovenous
Malformation (AVM).
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborators:
Boston Children's Hospital Boston Children’s Hospital